Oliclinomel N 4-550e

Valine, Alanine, Arginine, Histidine, Isoleucine, Leucine, Methionine, Phenylalanine, Proline, Serin, the active ingredient in Oliclinomel N 4-550e, is a mixture of essential and non‑essential amino acids presented as a sterile powder for intravenous use. It is intended for clinical situations that require amino acid supplementation, such as metabolic support during intensive care or peri‑operative care.

GNH USA supplies Oliclinomel N 4-550e as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and transplant centres worldwide.

Oliclinomel N 4-550e provides a broad spectrum amino‑acid formulation that supports patients with metabolic and nutritional needs in several clinical contexts: - Critical care: helps to maintain nitrogen balance and supports protein synthesis during intensive‑care treatment. - Peri‑operative care: contributes to tissue repair and wound healing during the surgical period. - Metabolic disorders: supplies essential amino acids for patients with inborn errors of metabolism or catabolic states. - Long‑term parenteral nutrition: serves as a component of total parenteral nutrition regimens for patients unable to receive enteral feeding.

Amino‑acid solutions administered intravenously can be associated with a range of reactions, most of which are mild and transient.

Common Side Effects: - Phlebitis at the infusion site: mild inflammation of the vein. - Transient hyperglycaemia: temporary rise in blood glucose levels. - Mild electrolyte imbalance: slight changes in serum potassium or calcium. - Nausea or mild gastrointestinal discomfort. - Low‑grade fever: mild increase in body temperature.

Serious or Rare Side Effects: - Anaphylactic reaction: severe allergy requiring immediate medical intervention. - Metabolic acidosis: significant shift in acid‑base balance. - Hyperosmolarity‑related complications: circulatory overload or renal strain. - Severe electrolyte disturbances: marked hyper‑ or hypokalemia. - Sepsis related to catheter contamination. - Acute liver dysfunction in susceptible patients.

When using Oliclinomel N 4-550e, clinicians should observe several safety measures: - Renal function monitoring: assess creatinine and urine output regularly. - Hepatic function monitoring: check liver enzymes and bilirubin levels. - Blood glucose monitoring: watch for hyperglycaemia, especially in diabetic patients. - Electrolyte surveillance: maintain serum potassium, calcium and magnesium within target ranges. - Infusion rate control: administer according to recommended flow rates to avoid osmotic stress. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Oliclinomel N 4‑550e may interact with other intravenous solutions and medications administered through the same line.

Major Interactions (Avoid): -    ​  Electrolyte‑    ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​ ​  ​  ​  ​  ​ -  L  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​ -  C ​ -  D -  E

Moderate Interactions (Monitor Closely): -    ​  ​  C ​  ​  ​  ​ -     -    d  t  t t

""""    " "" "